0QSS Stock Overview A biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
PHAXIAM Therapeutics S.A. Competitors Price History & Performance
Summary of share price highs, lows and changes for PHAXIAM Therapeutics Historical stock prices Current Share Price €1.71 52 Week High €4.22 52 Week Low €1.57 Beta 1.7 1 Month Change -0.47% 3 Month Change 0.71% 1 Year Change -61.27% 3 Year Change -91.92% 5 Year Change -97.47% Change since IPO -99.09%
Recent News & Updates
Phaxiam Therapeutics S.A. Presents Clinical Data of the Phagodair Pilot Study, with Results Confirming the Design of the Gloria Phase Ii Clinical Study Jan 01
PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S Nov 05
PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study Oct 10
PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus Apr 16
PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market Feb 23 PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market Feb 22
See more updates
Phaxiam Therapeutics S.A. Presents Clinical Data of the Phagodair Pilot Study, with Results Confirming the Design of the Gloria Phase Ii Clinical Study Jan 01
PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S Nov 05
PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study Oct 10
PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus Apr 16
PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market Feb 23 PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market Feb 22
No longer forecast to breakeven Feb 01 PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024
PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus Oct 25
New major risk - Revenue and earnings growth Oct 24
PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains Oct 12
PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq Oct 05
New major risk - Financial position Sep 29
PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development Sep 22 PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023
New major risk - Shareholder dilution Jul 30
ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index Jun 30 ERYTECH Pharma S.A Announces Management Changes
Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors Jun 24
Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes Jun 06
Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon. Feb 18
No longer forecast to breakeven Jan 05
Insufficient new directors Jan 05
No longer forecast to breakeven Nov 17
Insufficient new directors Nov 17
ERYTECH Announces Receipt of Nasdaq Notice Oct 14
ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022 Sep 28
Insufficient new directors Sep 27
ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL Aug 25
No longer forecast to breakeven Aug 09
Insufficient new directors Aug 09
Insufficient new directors Jul 02
No longer forecast to breakeven Jun 29
No longer forecast to breakeven Jun 02
No longer forecast to breakeven Apr 27
Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million. Apr 27 Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million. Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million. Apr 25
ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial Apr 07
ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases Feb 10
ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI Jan 24
No longer forecast to breakeven Nov 24
Forecast to breakeven in 2023 Sep 23
Revenue misses expectations Mar 10
New 90-day low: €6.70 Mar 06
ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis Feb 08
New 90-day high: €8.80 Jan 15
ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer Jan 15
ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer Dec 16
New 90-day high: €8.07 Dec 06
New 90-day high: €6.55 Nov 16
Revenue misses expectations Nov 07
ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting Nov 06 ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021
ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team Oct 27 Shareholder Returns 0QSS GB Biotechs GB Market 7D -2.6% 2.7% 0.8% 1Y -61.3% -24.0% 4.4%
See full shareholder returns
Return vs Industry: 0QSS underperformed the UK Biotechs industry which returned -24% over the past year.
Return vs Market: 0QSS underperformed the UK Market which returned 4.4% over the past year.
Price Volatility Is 0QSS's price volatile compared to industry and market? 0QSS volatility 0QSS Average Weekly Movement n/a Biotechs Industry Average Movement 9.1% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.5%
Stable Share Price: 0QSS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0QSS's volatility change over the past year.
About the Company PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
Show more PHAXIAM Therapeutics S.A. Fundamentals Summary How do PHAXIAM Therapeutics's earnings and revenue compare to its market cap? 0QSS fundamental statistics Market cap €17.04m Earnings (TTM ) -€21.92m Revenue (TTM ) €2.14m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0QSS income statement (TTM ) Revenue €2.14m Cost of Revenue €0 Gross Profit €2.14m Other Expenses €24.06m Earnings -€21.92m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -2.19 Gross Margin 100.00% Net Profit Margin -1,023.91% Debt/Equity Ratio 51.8%
How did 0QSS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 15:42 End of Day Share Price 2025/01/03 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources PHAXIAM Therapeutics S.A. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mathieu Chabert Bryan Garnier & Co Guillaume Cuvillier Gilbert Dupont Philippa Gardner Jefferies LLC
Show 5 more analysts 
